Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25987468 | 0.87 | TSHR (0.38) | TSHRALDH1A1 | |
| SCHEMBL823712 | 0.80 | CYP2C19 (0.39) | TSHRALDH1A1TP53HSD17B10MEN1 | |
| SCHEMBL5932437 | 0.78 | MEN1 (0.57) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL9361430 | 0.78 | MEN1 (0.57) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL7653445 | 0.78 | MEN1 (0.57) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL5932976 | 0.78 | MEN1 (0.57) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL7633832 | 0.78 | MEN1 (0.57) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL1315512 | 0.78 | ALDH1A1 (0.48) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL22129561 | 0.78 | ALDH1A1 (0.48) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL29842694 | 0.78 | ALDH1A1 (0.48) | TSHRALDH1A1TP53HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8142720-B2 | Molecules suitable for binding to a metal layer for covalently immobilizing biomolecules | IMEC (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20100284860-A1 | MOLECULES SUITABLE FOR BINDING TO A METAL LAYER FOR COVALENTLY IMMOBILIZING BIOMOLECULES | IMEC (BE) | 2010-11-11 | — | — | US | disclosed |
| US-7770437-B2 | Thiol or disulfide molecules having poly(ethylene oxide) groups for use in a self assembled monolayer bound to a metal layer for covalently immobilizing biomolecules in a biosensor | IMEC (BE) | 2010-08-10 | — | — | US | disclosed |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | IMEC (BE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284860-A1 | MOLECULES SUITABLE FOR BINDING TO A METAL LAYER FOR COVALENTLY IMMOBILIZING BIOMOLECULES | EBPL, SPR, MB | TSHR 1902/4885ALDH1A1 3655/4885TP53 2300/4885 |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | EBPL, AEBP2, NAPA | TSHR 1653/4885ALDH1A1 1605/4885TP53 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.